Background: There has been a significant increase in the number of patients presenting with cancer related emergencies and potentially requiring critical care admission. Aim: To analyse the short and long-term outcomes of patients with solid tumours requiring unplanned medical admission to a specialist cancer intensive care unit (ICU). Design: An unplanned cohort study. Methods: A retrospective analysis of patients admitted to a UK specialist tertiary oncology CCU between September 2009 and September 2015. The primary outcome measures were survival to CCU discharge and 1-year survival. Results: 687 patients had an unplanned medical admission. The most frequent primary tumours were lymphoma (22.1%), lung (15.2%) and colorectal (13.0%), and 181 (44.4%) were known to have metastases. The median Acute Physiology and Chronic Health Evaluation (APACHE) II and Intensive Care National Audit and Research Centre (ICNARC) scores were 21 and 17, respectively. ICU mortality was 26.7%, with total hospital mortality of 41.9%. The median survival of the total cohort was 56 days after ICU admission, with 107 patients surviving 365 days. Patients with metastatic disease were almost twice as likely to die within the year following ICU admission compared with their counterparts without metastases. Only pancreatic and lung primaries were shown to have a statistically significant impact on survival at 1 year. Pneumonia carried with it the worst prognosis (cumulative survival 0.11), followed by sepsis (0.25) and non-infective respiratory disease (0.26). Conclusions: The stage and type of cancer appear to have minimal impact on short-term ICU outcomes and only confer poorer long-term prognosis related to the disease.
Introduction
Cancer care has become increasingly specialized. As a result of these advances in care and the increasing number of patients receiving cancer therapies, there has been a significant increase in the number of patients presenting with cancer related emergencies and potentially requiring critical care admission. [1] [2] [3] These emergencies may relate directly to the cancer itself or be due to treatment toxicities. 3, 4 In total 5-10% of patients with cancer currently require intensive care unit (ICU) admission and patients with malignancies account for 20% of ICU admissions. 2, [4] [5] [6] [7] Traditionally, a diagnosis of cancer had been a common reason for patients to be declined admission to an intensive care bed. Determining which patients with cancer will benefit from critical care admission is challenging. Patients requiring elective post-operative critical care admission have good outcomes but in those with unplanned medical admissions experience is more disparate. 8 The difficulty, in part, relates to no reliable tools for prognostication in determining outcome, poor consistency in the reported studies and physiological scores not performing well in this cohort. The aim of this study was to analyse the short and longterm outcomes of patients with solid tumours requiring unplanned medical admission to a specialist cancer ICU. We will consider factors that are associated with poor prognosis, which may be able to assist clinicians in discussions with colleagues, patients and families as to the suitability of intensive care in patients with solid tumours.
Materials and methods
A retrospective study was performed at a specialist Oncology hospital in the North West of England based on data collected between September 2009 and September 2015. The hospital has 8 ICU beds, which takes elective post-operative surgical admissions and referrals from haemato-oncology inpatients and the acute admissions unit, supported by a Critical Care outreach service. Unplanned medical admissions to the ICU are made on discussion with treating physicians, oncologists and intensivists with the reversibility of the emergency presentation and overall prognosis from the malignant disease the key factors used in determining the decision. The ICU has fully computerized electronic notes where all medical and nursing notes, physiological observations, organ support and laboratory data are recorded.
Adult patients over the age 18 with solid tumours that had an unplanned medical admission to the ICU were included. We defined solid tumours as all carcinomas, sarcomas and lymphomas. Lymphoma patients admitted acutely to ICU were included in the analysis, as in our organisation those undergoing systemic anti-cancer treatment prior to a bone marrow transplant are managed by oncologists rather than haematologists. Only the first admission to the ICU was included. Patients with a liquid tumour, those who had an elective ICU admission and those on ICU for less than 24 h, as this precludes accurate calculation of the APACHE II score, were excluded.
Basic demographic data including patient age, gender, primary tumour site and presence of metastases alongside the reason for admission to ICU and the need for organ support were collected. Organ support was defined as mechanical ventilation for respiratory support, vasopressors for cardiovascular support, GCS <7 for neurological support and renal replacement therapy for renal support.
In addition, both the APACHE II and ICNARC prediction models for critical care mortality were calculated. The APACHE II score combines a physiological score with age, co-morbidities and the reason for admission in order to estimate the probability of ICU mortality. 9 The ICNARC score uses similar variables but does not assess co-morbidities. 10 The primary outcome measures were survival to ICU discharge and 1-year survival. Survival analysis statistics were used to assess each variable's effect on survival at 365 days. Multivariate analysis was undertaken, to calculate associations between primary predictors and length of survival, when controlling for other demographic, prognostic, clinical or confounding variables. Survival in days was used as the figure for time-to-event, with survival to 1 year being the dichotomous categorical outcome. Baseline values were chosen on the basis of the type of patients with good survival and following the normal curve of survival, as per the overall mortality graph. All variables were included in this calculation except the APACHE II and ICNARC data, to avoid collinearity due to other recorded data being components of the tools. Cox regression tables were also produced for both site of primary and cause of admission with other variables controlled for. This was repeated to look for To assess performance of the APACHE II and ICNARC scores, the ratio of predicted mortality values: actual number of deaths was calculated to assess overall accuracy. Receiver operator curves and Kaplan-Meier curves were also created.
Results
During the study period there were 3112 admissions to the ICU. Of these, 778 (25.0%) were unplanned medical admissions with 687 having the underlying diagnosis of a solid tumour. 108 of these were readmissions, 170 had ICU stays of <than 24 h and 1 patient was <18 years of age.
The remaining 408 patients were eligible for our study. 226 (55.4%) were male, and the median age was 63 years. The most frequent primary tumours were lymphoma (22.1%), lung (15.2%) and colorectal (13.0%), and 181 (44.4%) were known to have metastases. The most common causes of medical ICU admission included pneumonia, sepsis and cardiac events (see Table 1 ).
Over half of patients (53.2%) required organ support within their first 12 h of ICU admission though only 9.7% of these were for multiple organs. Mechanical ventilation was most commonly required followed by inotropic support. The median APACHE II and ICNARC scores were 21 and 17, respectively.
ICU mortality was 26.7%, with total hospital mortality of 41.9%. The median survival of the total cohort was 56 days after ICU admission, with 107 patients surviving 365 days (see Figure 1) .
Multivariate analysis showed age and the presence of metastases increase 365-day mortality (see Table 2 ). Patients with metastatic disease were almost twice as likely to die within the year following ICU admission compared with their counterparts without metastases.
Implementation of support for the neurological system increased hazard risk 7-fold. Neither the need for respiratory, cardiovascular or renal support significantly indicated a change in risk. Conversely, an increase in total number of organs supported appeared to consistently reduce risk of mortality within 365 days. The type of organ support and total number of organs supported are linearly dependent covariates, so the degree of importance of these factors may be disproportionately represented.
Of the various tumour sites present in our study, only pancreatic and lung carcinoma were shown to have a statistically significant impact on survival at 1 year, increasing mortality by 6-and 4-fold, respectively when compared with sarcoma patients, the group chosen for baseline. Cox regression analysis demonstrated pancreatic tumours had the worst prognosis (cumulative survival at 1 year 0.02), followed by lung (0.06) and then oesophageal (0.11). These disease groups also had lower survival outcomes at 1, 3 and 6 months, respectively (see Table 3 ).
Pneumonia had a significant increase in hazard risk, at five times the likelihood when compared with the baseline of seizure patients. Cox analysis of the reason for admission demonstrated that pneumonia carried with it the worst prognosis (cumulative survival 0.11), followed by sepsis (0.25) and noninfective respiratory disease (0.26) (see Table 3 ).
An increase in the total number of organs supported showed statistically significant increases in mortality risk at the ICU and Figure 2) . Patients who survived ICU admission had lower predicted mortality scores on both the APACHE II and ICNARC models than non-survivors. APACHE II non-survivors had a median risk of mortality of 0.42 (0.30-0.49) compared with 0.35 (0.26-0.44) for survivors (OR 1.13 (0.67-1.94) . Using the ICNARC model it was 0.29 (0.2-0.46) compared with 0.2 (0.12-0.31); OR 2.25 (1.13-4.5). Observed ICU mortality was lower than predicted by the APACHE II score in most of the disease groups with the exception of lung cancer (see Table 4 ). The APACHE II AUC was 0.59 (95% CI: 0.53-0.65); compared with 0.68 (95% CI: 0.62-0.73) for ICNARC.
Discussion
Outcomes, such as mortality, vary widely in patients with cancer admitted to ICU. 5, 7 This reflects the challenges of prognostication in critically ill patients with cancer and the marked variations in clinical practice with regards to their management and criteria for ICU admission. In Oncology patients, the selection of those who may benefit from Critical Care admission is crucial. This in part is driven by the limited availability of Critical Care beds. It is also important to avoid futile ICU admissions and interventions for those in the terminal phases of life to prevent unrealistic expectations and suffering for both the patient and their families. This study helps to further define which cancer patients are likely to benefit from critical care admission, which can aid both clinician and family decision making.
The stage and type of cancer appear to have minimal impact on short-term ICU outcomes and only confer poorer long-term prognosis related to the disease. 6, 11, 12 One study analysing 120 Figure 2 . Survival of patients at discharge from ICU, discharge from hospital and 365-day survival based on the initial organ support requirement. consecutive ICU cancer admissions found that 30-day mortality was not correlated with disease stage. 13 Our study confirms these findings with the underlying disease only affecting longterm (365 days) survival. Our study demonstrates that short-term mortality and outcome is highly correlated with the degree of organ support required. Increasing numbers of organ failures are associated with a corresponding decrease in survival. 14, 15 Our findings suggest this impact is much less defined for long-term survival suggesting other factors in patients with cancer are more important than a period of critical illness. The need for early identification and ICU admission in patients with cancer at risk of deterioration is well established. Disease severity scoring systems, such as APACHE II and Sepsis Organ Failure Assessment (SOFA), and physiological track and trigger systems, such as the MEWS (Modified Early Warning Score), perform poorly in patients in cancer. [16] [17] [18] Furthermore,
cancer-specific models, such as the ICU cancer mortality model, do not perform substantially better than the general prediction tools. 19 Alongside this, bedside evaluation has also been shown to be an unreliable predictor of outcome for critically unwell patients with cancer. In a French study 21.3% of patients determined too well for ICU admission died within 30 days and 16.7% considered too sick for ICU still alive at 180 days. 20 The absence of a high-performing validated score for the identification of critically ill cancer patients is not surprising given the heterogeneity of cancer types, variable cancer-treatment options, the effect of co-morbidities and the variation in approaches to ICU admission. As continued improvements in Oncology and Intensive Care treatments occur these decisions will become more challenging and the demand for Critical Care beds in this cohort is likely to increase. This necessitates constantly re-evaluating selection criteria for ICU admission for cancer patients as novel therapies alter long-term outcomes. Prospective studies, particularly those incorporating long term and quality of life measures, are required to inform decision making in this increasingly challenging area.
